Clinical trial / 2018
Adjuvant resveratrol supplementation for 3 months significantly lowered clinical and biochemical disease markers in patients with rheumatoid arthritis.
A randomized controlled clinical trial evaluated 100 patients with rheumatoid arthritis divided into two groups of 50. The intervention group received a daily 1 g resveratrol capsule alongside conventional treatment for 3 months, while the control group received regular treatment alone. Clinical markers (28-joint count for swelling and tenderness) and disease activity score for 28 joints were significantly lowered in the resveratrol group. Additionally, serum levels of C-reactive protein, erythrocyte sedimentation rate, undercarboxylated osteocalcin, matrix metalloproteinase-3, tumor necrosis factor alpha, and interleukin-6 significantly decreased in resveratrol-treated patients.
- Study type
- Randomized controlled clinical trial
- Who was studied
- 100 rheumatoid arthritis patients (68 female, 32 male)
- What was measured
- Clinical markers (28-joint count for swelling/tenderness, DAS-28) and biochemical markers
THE PAPER
Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study.
Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Clin Rheumatol, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.